Navigation Links
Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
Date:6/3/2008

ology into valuable product opportunities." said Foamix CEO, Dr. Dov Tamarkin. "In addition, this is one more step towards achieving Foamix's mission, improving the quality of patients' lives."

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialty pharmaceutical company focused on the development of topical foam products for prescription, OTC and cosmetic applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. We currently collaborate with 10 pharmaceutical companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs; and we have our own in-house pipeline of dermatological and gynecological drugs in foam presentation.

The company's development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix holds 4 US patents and has 65 US patents pending, with corresponding national applications worldwide.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il

About Ferndale

Ferndale Laboratories specializes in high-value, brand name products that help relieve discomfort and promote healing for patients who show symptoms of inflammatory and pruritic cutaneous conditions.

The Company is dedicated to discovering, developing and delivering unique, value-added Dermatology therapies that help heal, protect and beautify the skin.

Read more on http://www.ferndalelabs.com.


'/>"/>
SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
6. Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
7. BMP Sunstone Receives Import Drug License (IDL) from SFDA
8. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
11. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Company (NYSE: MOS ) plans to issue ... financial tables on Tuesday, January 5, 2010, after the ... Results will be available on Mosaic,s website at ... conference call with presentation slides on Wednesday, January 6, ... begin at 11:00 a.m. Eastern Standard Time (10:00 a.m. ...
(Date:12/15/2009)... 15 The Center for Business ... is pleased to announce the full agenda ... and Reporting Congress . The forum will ... March 16-17, 2010. ,, Over 1,500 senior-level ... attended this premier event since its inception, ...
(Date:12/15/2009)... -- Thomson Reuters today ... the first drug pipeline database to fully integrate ... highly anticipated new content is being provided to ... ,, Thomson Pharma will offer drug ... releases, conferences, and other sources across all therapeutic ...
(Date:12/15/2009)... the launch of several innovative new programs to aid ... current economic climate. The first is aimed at ... services over a period of 6, 12, 18, or ... companies. The second is aimed at more established ... 6 to 12 month period at discounted rates, and ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2
... to the demand in food, beverage and nutritional ... chemical company, Albemarle Corporation, (NYSE: ALB ... joined forces to scale-up production of Zymes, proprietary ... technology promotes the clear dissolution of non-water-soluble vitamins ...
... Provides Ease, Efficacy and Excellent TolerabilityCORONA, Calif., Jan. 27 ... a leader in generic and specialty branded pharmaceuticals, announced ... has approved GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first ... bladder (OAB) with symptoms of urge urinary incontinence, urgency, ...
... Inc. (Nasdaq: ENCO ) , a full ... development, and management capabilities for clinical trials and patient ... today announced the signing of $3.1 million of new ... current U.S. oncology clinical trial with a major global ...
Other Biology Technology:Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 4Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 2Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 3
(Date:12/14/2009)... Society (BMES) have founded a new journal Cardiovascular ... CVET is a forum for research on all ... first issue of the new quarterly journal will appear ... at Springer, Annals of Biomedical Engineering and ... Engineering and Technology will present a wide spectrum ...
(Date:12/14/2009)... Convention on Climate Change taking place in Copenhagen, ... Trend, event on Sunday evening to provide a ... of the new ,Environmental Atlas of Europe,. , ... of the European Environment Agency (EEA), the UN ... of short films showing the significance of environmental ...
(Date:12/13/2009)... team led by Yale University researchers has used ... for the first time. Their findings, which appear ... Nature Nanotechnology , could dramatically simplify the ... other diseases. , The teamled by ... & Applied Science, and Tarek Fahmy, an associate ...
Breaking Biology News(10 mins):Biomedical Engineering Society's new journal to be published by Springer 2'Environmental Atlas of Europe' unveiled at COP15 2Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Hoag Hospital Certified as Baby Friendly Facility 52982 1Hoag Hospital Certified as Baby Friendly Facility 52982 2Hoag Hospital Certified as Baby Friendly Facility 52982 3Test helps in fight against lung infections and for treating other life threatening infections 9399 1Test helps in fight against lung infections and for treating other life threatening infections 9399 2Test helps in fight against lung infections and for treating other life threatening infections 9399 3Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 1Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 2Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 3Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 4
... movement is defined has profound implications for where evangelicals ... by sociologists at Rice University and the University of ... debate over whether Sen. Obama can shave off enough ... D. Michael Lindsay, one of the researchers. "That depends ...
... the University of York have discovered a ,Chemical Equator, ... from the largely uncontaminated atmosphere of the Southern Hemisphere. ... evidence for an atmospheric chemical equator around 50 km ... findings show for the first time that the chemical ...
... (TSC) is yielding insight into a possible cause of ... cells. Researchers in the F.M. Kirby Neurobiology Center at ... and Xi He, PhD, also found that normal neuronal ... could be done safely in humans, it might be ...
Other Biology News:New study looks to define evangelicals and how they affect polling 2'Chemical equator' discovery will aid pollution mapping 2Rare genetic disorder gives clues to autism, epilepsy, mental retardation 2
TP-1 (NDOG1)...
... porcine) Endogenous potent vasoconstrictor peptide. ... and modulates vascular tonus. ET-1, ET-2, and ... endothelin genes. ET-2 and ET-3 are similar ... six amino acids, respectively. All three isopeptides ...
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
GLP-1 (HYB 147-12)...
Biology Products: